Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
Baxter
Colorcon
Johnson and Johnson
Mallinckrodt

Last Updated: December 7, 2022

Details for Patent: 8,632,802


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which drugs does patent 8,632,802 protect, and when does it expire?

Patent 8,632,802 protects DAYTRANA and XELSTRYM and is included in two NDAs.

This patent has one patent family member in one country.

Summary for Patent: 8,632,802
Title:Device for transdermal administration of drugs including acrylic polymers
Abstract: A transdermal delivery system is provided where the drug delivery rates, onset and profiles of at least one active agent are controlled by selectively manipulating the monomeric make up of an acrylic-based polymer in the transdermal drug delivery system. The drug carrier composition may be comprised of (a) one or more acrylic-based polymers having one or more different monomers selected from the group consisting of hard and soft monomers; (b) one or more silicone-based polymers; and (c) one or more active agents where the device provides a desired solubility for the active agent and controls drug delivery rates, onset and profiles of at least one active agent.
Inventor(s): Kanios; David (Miami, FL)
Assignee: Noven Pharmaceuticals, Inc. (Miami, FL)
Application Number:13/229,007
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,632,802
Patent Claim Types:
see list of patent claims
Composition; Delivery; Use; Device;

Drugs Protected by US Patent 8,632,802

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Noven Pharms Inc DAYTRANA methylphenidate FILM, EXTENDED RELEASE;TRANSDERMAL 021514-001 Apr 6, 2006 AB RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Noven Pharms Inc DAYTRANA methylphenidate FILM, EXTENDED RELEASE;TRANSDERMAL 021514-002 Apr 6, 2006 AB RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Noven Pharms Inc DAYTRANA methylphenidate FILM, EXTENDED RELEASE;TRANSDERMAL 021514-003 Apr 6, 2006 AB RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Noven Pharms Inc DAYTRANA methylphenidate FILM, EXTENDED RELEASE;TRANSDERMAL 021514-004 Apr 6, 2006 AB RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Noven Pharms Inc XELSTRYM dextroamphetamine SYSTEM;TRANSDERMAL 215401-001 Mar 22, 2022 DISCN Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,632,802

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
World Intellectual Property Organization (WIPO) 2006041911 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
McKesson
Harvard Business School
Moodys
Boehringer Ingelheim
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.